Metagenomi reports $140.2M cash; MGX-001 IND on track for Q4 2026

Metagenomi Therapeutics, Inc.

2026-Q1 EPS reported -$0.61 revenue$1,248,000

Cash, equivalents and marketable securities of $140.2M at March 31, 2026; runway through Q4 2027.
MGX-001 for hemophilia A: regulatory submission including IND planned for Q4 2026, first-in-human trials in 2027.
Kapil Saxena, MD, appointed to lead clinical development for MGX-001; prior roles at Autolus, Bayer, Daiichi Sankyo.
R&D expenses $19.3M in Q1 2026 (vs $25.1M Q1 2025); G&A $6.5M (vs $6.8M).
Nature publication on compact CRISPR nuclease MG119-28 with enhanced editing efficiency.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Metagenomi Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

today reported financial results for the first quarter ended March 31, 2026, and provided business updates.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Metagenomi Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 11, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and additional business updates.

View on SEC.gov

Browse all earnings releases →

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216763

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.